MetaCap

Belite Bio (BLTE) vs Dianthus Therapeutics (DNTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dianthus Therapeutics (DNTH) has outperformed Belite Bio (BLTE) over the past year, gaining 104.0% versus a gain of 5.7%. Belite Bio is the larger company by market cap ($5.17 billion vs $4.76 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLTE+5.66%DNTH+103.98%
+189%+84%-22%
Nov 21, 20251 yearNov 20, 2026
BLTE+1102.83%DNTH+269.54%
+1818%+827%-165%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLTE versus DNTH key metrics
MetricBLTEDNTH
Share price$127.38$84.55
Market cap$5.17B$4.76B
1-day change-15.65%-0.33%
YTD return-20.37%+105.17%
1-year return+5.66%+103.98%
5-year return—-12.80%
EPS (TTM)$-2.84$-4.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.04M
Revenue growth (YoY)—-67.35%
Net income (latest FY)$-77.61M$-162.34M
Operating margin—-8739.34%
Net margin—-7973.33%
52-week high$200.00$117.88
52-week low$115.41$35.84
Distance from 52-week high-36.31%-28.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+82.92%+64.70%
Average volume195.65K848.96K
Shares outstanding40.61M56.31M
Employees4192
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNTH has outperformed BLTE by 98.3 percentage points over the past year.

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

About Dianthus Therapeutics

DNTH stock →

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

BLTE vs DNTH FAQ

Which is bigger, Belite Bio or Dianthus Therapeutics?

Belite Bio (BLTE) is larger, with a market capitalization of $5.17B compared with $4.76B for Dianthus Therapeutics (DNTH).

Which stock has performed better over the past year, BLTE or DNTH?

DNTH returned +103.98% over the past 12 months, compared with +5.66% for BLTE (price return, excluding dividends). Past performance does not predict future results.

Are Belite Bio and Dianthus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons